GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Heartseed Inc (TSE:219A) » Definitions » Marketable Securities

Heartseed (TSE:219A) Marketable Securities : 円0.0 Mil (As of Oct. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Heartseed Marketable Securities?

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Heartseed's Marketable Securities for the quarter that ended in Oct. 2024 was 円0.0 Mil.


Heartseed Marketable Securities Historical Data

The historical data trend for Heartseed's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Heartseed Marketable Securities Chart

Heartseed Annual Data
Trend Oct22 Oct23 Oct24
Marketable Securities
- - -

Heartseed Semi-Annual Data
Oct22 Oct23 Apr24 Oct24
Marketable Securities - - - -

Heartseed Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Heartseed  (TSE:219A) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".


Heartseed Marketable Securities Related Terms

Thank you for viewing the detailed overview of Heartseed's Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Heartseed Business Description

Traded in Other Exchanges
N/A
Address
1-2-3 Shibaura, Minato-ku, Tokyo, JPN, 105-0023
Heartseed Inc is engaged in developing and commercializing iPS cell-derived cardiomyocyte replacement therapy for advanced heart failure.

Heartseed Headlines

No Headlines